Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
- PMID: 34380530
- PMCID: PMC8356386
- DOI: 10.1186/s13058-021-01459-y
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Abstract
The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibody-drug conjugates (ADCs) are a class of therapeutics that combines an antigen-specific antibody backbone with a potent cytotoxic payload, resulting in an improved therapeutic index. Two anti-HER2 ADCs have been approved by the FDA with different indications in HER2-positive breast cancer. Ado-trastuzumab emtansine (T-DM1) was the first-in-class HER2-targeting ADC, initially approved in 2013 for metastatic patients who previously received trastuzumab and a taxane, and the label was expanded in 2019 to include adjuvant treatment of high-risk patients with residual disease after neoadjuvant taxane and trastuzumab-based therapy. In 2020, trastuzumab deruxtecan (T-DXd) was the second approved ADC for patients who had received at least 2 lines of anti-HER2-based therapy in the metastatic setting. The success of these two agents has transformed the treatment of HER2-positive breast cancer and has re-energized the field of ADC development. Given their advanced pharmaceutical properties, next-generation HER2-targeted ADCs have the potential to be active beyond traditional HER2-positive breast cancer and may be effective in cells with low expression of HER2 or ERBB2 mutations, opening a spectrum of new possible clinical applications. Ongoing challenges include improving target-specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection. The aim of this review is to summarize the principal molecular, clinical, and safety characteristics of approved and experimental anti-HER2 ADCs, contextualizing the current and future landscape of drug development.
Keywords: ADCs; Anti-HER2 ADCs; Anti-HER2 antibody conjugate; Antibody-drug conjugate; HER2-positive breast cancer; Novel anti-HER2 ADCs.
© 2021. The Author(s).
Conflict of interest statement
JZD has received honorarium from OncLive. SM has received research funding and/or honoraria for consultation and speaking fees from Genentech, Daiichi Sankyo, AstraZeneca, Seattle Genetics, and Macrogenics.
References
-
- Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, Agajanian R, Ahmad R, Aktas B, Alencar VH, Amadori D, Andrade J, André Franke F, Angiolini C, Aogi K, Armor J, Arpornwirat W, Assersohn L, Audeh W, Aulitzky W, Azevedo S, Bartoli MA, Batista Lopez N, Bianconi M, Biganzoli L, Birhiray R, Bitina M, Blachy R, Blackwell K, Blanchard R, Blanchet P, Boiangiu I, Bower B, Brezden-Masley C, Brufsky A, Budde L, Caguioa P, Calvo L, Campone M, Carroll RR, Castro H, Chan V, Charu V, Cinieri S, Clemens M, Conejo EA, Côrtes E, Coudert B, Cronemberger E, Cubero D, Dakhil S, Daniel B, Davidson N, de Fatima Gaui M, de la Cruz S, del Pilar M, Delgado G, Ellerton JA, Estuardo C, Fehrenbacher L, Ferrero JM, Flynn PJ, Foszczynska-Kloda M, Franco S, Fujii H, Gallagher C, Gamucci T, Giacomi N, Gil I Gil M, Gonzalez Martin A, Gorbunova V, Gotovkin E, Green N, Grincuka E, Grischke EM, Hansen V, Hargis J, Hauschild M, Hegg R, Hendricks C, Hermann R, Hoff P, Horiguchi J, Hornedo Muguiro J, Iacobelli S, Inoue K, Ismael G, Itoh Y, Iwata DH, Jendiroba D, Jochim R, Jones A, Just M, Kallab A, Karwal M, Kashiwaba M, Kato G, Kaufman PA, Kellokumpu-Lehtinen P, Kirsch A, Kiselev I, Klein P, Kohno N, Kopp M, Kostovska-Maneva L, Kotliar M, Kudaba I, Kümmel S, Kuroi K, Lacava J, Latini L, Lee SC, Lichinitser M, Lobo C, Maintz C, Maneecahvakajorn J, Marmé A, Martinez G, Masuda N, Matwiejuk M, Merculov V, Michaelson R, Miguel L, Monroy H, Montemurro F, Morales S, Moura R, Mueller V, Mulatero C, Nakagami K, Nakayama T, Neidhart J, Nguyen A, Nishimura R, Ogata H, O'reilly S, O'rourke T, Otero Reye D, Ouyang X, Patel R, Patel T, Pedrini JL, Pereira R, Perez A, Peterson C, Pienkowski T, Pinczowski H, Polikoff J, Polkowski W, Price PE, Prill S, Priou F, Purkalne G, Pyrhoenen S, Quackenbush R, Rai Y, Ribelles N, Ro J, Robinson A, Robles R, Rodriguez G, Roman L, Saji S, Sanchez-Rovira P, Sato N, Schmidt M, Schumacher C, Senecal F, Sharma P, Shen Z, Shirinkin V, Simoncini E, Sirisinha T, Smith R, Sohn JH, Soldic Z, Soria T, Spicer D, Srimuninnimit V, Sriuranpong V, Staroslawska E, Stefanovski P, Sunpaweravong P, Taguchi J, Takeda K, Tellez-Trevilla G, Thomas R, Thomssen C, Toache Z, Tokuda Y, Tomczak P, Tosello C, Tsugawa K, Tudtud D, Ueno T, van Eyll B, Varela M, Vasev N, Vrbanec D, Wang X, Wang L, Watanabe J, Waterhouse D, Wesenberg B, Wheatley D, Wong ZW, Yadav S, Yadav S, Yardley D, Yau TK, Yeo W, Ying C, Youn Oh D. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi: 10.1016/S1470-2045(19)30863-0. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
